Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Xue E, Lorentino F, Pavesi F, Assanelli A, et al. Leuk Res 2021;109:106642.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xue E, Lorentino F, Pavesi F, Assanelli A, et al. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Leuk Res 2021;109:106642.
PMID: 34157510